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ABSTRACT 
Objective: Aim of the present research work was to develop a sensitive, rapid and accurate, stability-indicating RP-UPLC method for the 
simultaneous estimation of tezacaftor and ivacaftor in formulations.  
Methods: The chromatographic separation of the mixture of tezacaftor and ivacaftor was attained in isocratic method utilizing a mobile phase of 0.1 
% orthophosphoric acid and acetonitrile in the proportion of 50:50%v/v utilizing a HSS C18 column which has dimensions of 100×2.1 mm, 1.7  
particle size and the flow rate of 0.3 ml/min. The detection system was monitored at 292 nm wavelength maximum with 1.5 l injection volume. 
The present method was validated as per the guidelines given by the ICH for specificity, accuracy, sensitivity, linearity and precision. 
Results: The retaining time for tezacaftor and ivacaftor were achieved at 1.071 min and 0.530 min, respectively. Tezacaftor, ivacaftor and their 
combined drug formulation were exposed to thermal, acidic, oxidative, photolytic, and alkaline conditions. The developed method was highly 
sensitive, rapid, precise and accurate than the earlier reported methods. The total run time was decreased to 2.0 min; hence, the technique was 
more precise and economical. Stability studies directed for the suitability of the technique for degradation studies of tezacaftor and ivacaftor.  
Conclusion: The projected method can be utilized for routine analysis in the quality control department in pharmaceutical trades. 
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INTRODUCTION 
Tezacaftor (TZR) and ivacaftor (IVR) drugs were combined in a 
single dosage form (tablet) in the brand name of symdeko, used to 
treat cystic fibrosis (CF) in patients more than six years old having 
genetically specific mutations. A wide variety of cystic fibrosis 
transmembrane regulator (CFTR) mutations correlate to the CF-
phenotype and are accompanied with different severity stages of the 
disease [1, 2]. The most common mutation, affecting approximately 
70% of patients with CF worldwide, is known as F508del-CFTR or 
delta-F508 (ΔF508), in which a deletion in the amino acid 
phenylalanine at 508-position resulting in impaired production of 
protein CFTR, thereby producing a significant decrease in the 
quantity of ion transporter present on cell membranes. Ivacaftor as 
monotherapy has failed to show a benefit for patients with delta-
F508 mutations, most likely due to an insufficient amount of protein 
available at the cell membrane for interaction and potentiation by 
the drug. CFTR correctors such as tezacaftor aim to repair F508del 
cellular misprocessing. This is done by modulating the position of 
the CFTR protein on the cell surface to the correct position, allowing 
for adequate ion channel formation and increased in water and salt 
movement through the cell membrane. The concomitant use of 
ivacaftor is intended to maintain an open channel, increasing the 
transport of chloride, reducing thick mucus production [3-5]. 
TZR chemically designated as 1-(2, 2-Difluoro-1, 3-benzodioxol-5–yl)–N-
[1-[(2R)-2,3-dihydroxypropyl]-6–fluoro–2-(2-hydroxy-1, 1–dimethyl 
ethyl)-1H–indol–5-yl]–cyclopropanecarboxamide with molecular weight 
of 520.505 g/mol. IVR chemically designated as N-(2, 4-Di-tert–butyl-5-
hydroxyphenyl)-4-oxo-1, 4-dihydroquinoline-3-carboxamide with 
molecular weight of 392.49g/mol (fig. 1) (Rowe and Verkman, 2012; 
Mohan, et al., 2017). The literature review discloses that a very few UPLC 
[6-8] and high performance liquid chromatographic techniques [9-13] 
have been reported for the estimation of TZR and IVR. Based on the 
reported HPLC methods, there is a need to develop a rapid, sensitive 
reversed-phase UPLC method for simultaneous estimation of TZR and 
IVR in bulk and formulations. 
 
Fig. 1: Structures of A) ivacaftor and B) tezacaftor 
 
MATERIALS AND METHODS 
Chemicals and reagents 
The standard components of TZR and IVR were provided as a gift 
sample from MSN Laboratories, Hyderabad, India. Symdeko tablets 
labeled to contain TZR 100 mg and IVR 150 mg were procured from 
the local market. HPLC grade acetonitrile was obtained from A. B 
enterprises, Mumbai, India. Orthophosphoric acid was bought from 
Ranchem, Mumbai, India. HPLC grade water was processed by 
utilizing Milli-Q Millipore water purification system used during the 
method development. 
Liquid chromatography 
Chromatographic system of Waters UPLC system furnished with 
photodiode array detector, auto-sampler, and HSS C18 column 
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which have dimensions of 100 × 2.1 mm, 1.7 particle size. The 
output signal was monitored and integrated utilizing water 
Empower-2.0 software. The isocratic mobile consisting of 0.1% 
orthophosphoric acid and acetonitrile in the proportion of 
50:50%v/v, pumped through the HSS C18 (100 × 2.1 mm, 1.7) 
column at a fixed flow of 0.3 ml/min. The injection volume of 1.5 l 
was utilized to measure the chromatograms at 292 nm as the 
wavelength maximum in the detection system.  
Preparation of buffer 
To prepare 0.1% orthophosphoric acid buffer 1 ml of orthophosphoric 
acid was diluted to 1000 ml with HPLC grade water. 
Preparation of stock and standard solutions 
Accurately Weighed and transferred 25 mg of TZR and 37.5 mg of 
IVR working Standards into a 25 ml clean dry volumetric flask, add 
3/4th volume of diluent (Water: ACN (50:50)), sonicated for 5 min 
and made up to the final volume with diluent to get 1000 µg/ml of 
TZR and 1500 µg/ml of IVR (stock solution). 1 ml of the resulting 
solution was transferred into a 10 ml volumetric flask and made up 
to 10 ml to get 100 µg/ml of TZR and 150 µg/ml of IVR. 
Preparation of sample solution 
20 tablets were weighed and calculated the average weight of tablets 
and then the weight equivalent to 1 tablet was transferred into a 100 
ml volumetric flask containing 50 ml of diluent and sonicated for 
25.0 min. Further, the volume made up with diluent and subjected 
for filtration by HPLC filters (1000 µg/ml of TZR and 1500 µg/ml of 
IVR). From the filtrate 1.0 ml solution was pipetted out into a 10.0 
ml volumetric flask and made up to 10.0 ml with diluent to get 100 
µg/ml of TZR and 150µg/ml.  
Analytical method validation 
The developed method for TZR and IVR was subjected for validation 
for the parameters like limit of detection (LOD), limit of 
quantification (LOQ), linearity, robustness, precision, system 
suitability and accuracy as per the guidelines of ICH [14-16]. 
RESULTS AND DISCUSSION 
Optimized chromatographic conditions 
After systematic trials with different mobile phase compositions and 
other parameters involved in the technique, HSS C18 100x 2.1 mm 
1.7 column, isocratic mobile consisting of 0.1% orthophosphoric 
acid and acetonitrile in the proportion of 50:50%v/v, column oven 
temperature of 30 °C with 1.5 ml injection volume, 0.3 ml/min flow 
rate and detection wavelength of 292 nm were optimized. Water and 
acetonitrile in the ratio of 50:50 %v/v was utilized as diluent.  
Specificity 
It is the ability of a method to unequivocally evaluate the analyte 
components in the presence of other components like impurities, 
degradants and excipients etc. expected to be present. This 
parameter was estimated by injecting and evaluating the blank, 
placebo, standard and sample solutions and chromatograms, 
respectively. Chromatograms of blank, placebo, and sample solution 
shown no peaks at the retaining time of TZR and IVR peaks. The 
chromatograms of TZR and IVR of standard, blank, formulation, and 
placebo were represented in fig. 2. 
 
 
Fig. 2: Chromatograms of A) blank, B) placebo, C) standard and D) formulation 
 
Linearity  
Aliquots of 0.25, 0.50, 0.75, 1.0, 1.25, and 1.50 ml of standard stock 
solution were pipetted out from the standard stock solution of 
concentration 1000 µg/ml of TZR and 1500 µg/ml of IVR and made 
up to 10.0 ml mark with diluent. The resulting solutions were come 
into 25 to 150 µg/ml of TZR and 37.5 to 225 µg/ml of IVR 
concentration range. The resulting linearity solutions were infused 
into a chromatographic system and form the chromatograms 
linearity graph was plotted by taking the peak area on Y-axis and 
concentration on X-axis. The calibration graphs were shown in fig. 3, 
4 and table 1, and all findings were within limits. 
 
Table 1: Calibration curve data of TZR and IVR 
TZR IVR 
Concentration (µg/ml) Peak area Concentration (µg/ml) Peak area 
25 58564 37.5 81688 
50 122099 75 164210 
75 182333 112.5 245933 
100 245412 150 324531 
125 298585 187.5 403615 
150 355250 225 484784 
Regression equation 
y = 2384.4x+1488 y = 2151x+1552.3 




Six replicates of the standard reference solution were 
infused to perform the system suitability parameter and the 
 
S. No. Peak name Peak area
1 IVR 324491 
2 TZR 245595 
 
LOD and LOQ 
LOD and LOQ parameters for TZR and IVR were calculated form the 
linear regression equation. Linearity values, graph and regression 
equation, were got from the linearity study and the LOD and LOQ 
values were represented in the table 3. 
Precision 
Analytical method precision is defined as the closeness of agreement 
between the replicate measurements of the analyte. It is expressed 
as the percentage coefficient of correlation or relative standard 
deviation (RSD) of the replicate measurements.
  
Table 3: Limit of detection and limit of quantification results
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Fig. 3: Linearity of tezacaftor 
 
Fig. 4: Linearity of ivacaftor 
 
processed and 
resulting chromatograms peak area, 
count, and tailing were measured
suitability parameter were 
chromatograms were given in fig
Table 2: TZR and IVR system suitability results 




System precision  
Working standard preparation of 1.5 µl solution was infused six 
times into the chromatographic system and chromatograms were 
obtained. %RSD of the peak area was calculated. The findings of 
system precision were shown in table 4.
Method precision 
Working sample solutions of 1.5 µl w
chromatographic system and chromatograms were obtained. The 
%RSD of the assay result of six preparations was determined. The 
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Table 4: System precision data 
S. No. Peak area response of drugs 
 TZR  IVR 
1 245595 325617 
2 246876 329213 
3. 243399 325596 
4 247294 324491 
5 244267 324384 
6 244682 326175 
Average 245304 325913 
STDV 1522.7 1761.1 
% RSD 0.6 0.5 
STDV: Standard deviation; RSD: Relative Standard deviation 
 
Table 5: Method precision results 
S. No. Peak area response of drugs 
 TZR  IVR 
1 249019 325135 
2 243712 330729 
3. 245330 328369 
4 243060 323782 
5 243574 323587 
6 244391 323907 
Average 244848 325918 
STDV 2188.6 2959.9 
% RSD 0.9 0.9 
STDV: Standard deviation; RSD: Relative Standard deviation 
 
Table 6: Intermediate precision results 
S. No. Peak area response of drugs 
 IVR  TZR 
1 279082 230390 
2 278896 232505 
3. 286045 232781 
4 282942 235868 
5 284263 233126 
6 286001 232951 
Average 282872 232937 
STDV 3224.0 1750.7 
% RSD 1.1 0.8 
STDV: Standard deviation; RSD: Relative Standard deviation 
 
Table 7: Percentage recovery results 















% recovery Mean % 
recovery 
50% 50 50.53892 101.08 100.21 75 74.90 99.87 99.97 
 50 50.04655 100.09 75 74.55 99.40 
50 49.86412 99.73 75 74.89 99.86 
100% 100 100.4525 100.45 150 150.601 100.40 
100 101.0942 101.09 150 150.1342 100.09 
100 100.3124 100.31 150 148.3722 98.91 
150% 150 149.878 99.92 225 227.7316 101.21 
150 149.6548 99.77 225 225.3397 100.15 
150 149.2275 99.48 225 224.5833 99.81 
 
Intermediate precision  
Working standard preparation of 1.5 µl was infused six times test 
preparations into the chromatographic system and chromatograms 
were obtained. The %RSD was evaluated for peak areas. The 
findings of intermediate precision study were represented in table 6. 
Accuracy 
A known amount of IVR and TZR at each three concentration levels 
of 50%, 100%, and 150% was added to a pre-analyzed sample 
solution and injected in triplicate at each level into the 
chromatographic system. The mean percentage recovery of IVR and 
TZR at each level was estimated. The findings were represented in 
tables 7. 
Robustness 
Working standard solution prepared as per test method was infused 
into the chromatographic system at variable conditions such as flow 
rate at±0.1 ml/min, mobile organic phase composition by±10%, and 
column temperature by±5 °C. The results of the robustness study 
parameter like peak area, retention time, plate count and tailing 
factor were within the limits. 
Forced degradation studies 
Acid degradation studies 
To 1 ml of stock s solution IVR and TZR, 1 ml of 1N Hydrochloric acid 
were added and refluxed for 30 min at 60 °C. The resultant solution 
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was diluted to obtain 100 µg/ml of TZR and 150 µg/ml of IVR 
solution and 1.5 µl solution was injected into the chromatographic 
system and the chromatograms were recorded to assess the stability 
of sample (fig. 5 and table 8) [17, 18]. 
 
 
Fig. 5: Chromatogram for acid degradation study 
 
Table 8: Results of stress degradation study 
S. No. Degradation condition TZR IVR 
 % recovery % Degraded % recovery % Degraded 
1 Acid hydrolysis 92.16 7.84 91.59 8.41 
2 Base hydrolysis 93.56 6.44 92.82 7.18 
3 Peroxide 93.19 6.81 94.82 5.18 
4 Dry heat 97.98 2.02 96.60 3.40 
5 Photostability 98.46 1.54 97.88 2.12 
6 Water sample 99.51 0.49 99.14 0.86 
 
Oxidation 
To 1 ml of stock solution of VXR, SFR and VLR, 1 ml of 10% hydrogen 
peroxide (H2O2) was added separately. The solutions were kept for 30 
min at 60 °C. For UPLC study, the resultant solution was diluted to obtain 
100 µg/ml of TZR and 150 µg/ml of IVR solution and 1.5 µl solution was 
injected into the chromatographic system and the chromatograms were 
recorded to assess the stability of sample (fig. 6 and table 8). 
Alkali degradation studies 
To 1 ml of stock solution VXR, SFR and VLR, 1 ml of 1N sodium 
hydroxide were added and refluxed for 30 min at 60 °C. The 
resultant solution was diluted to obtain 100 µg/ml of TZR and 
150µg/ml of IVR solution and 1.5 µl solution was injected into the 
chromatographic system and the chromatograms were recorded to 
assess the stability of sample (fig. 7 and table 8) [18, 19]. 
Dry heat degradation studies 
The standard drug solution was placed in an oven at 105 °C for 6 h 
to study dry heat degradation [20]. For UPLC study, the resultant 
solution was diluted obtain 100 µg/ml of TZR and 150 µg/ml of IVR 
solution and 1.5 µl solution was injected into the chromatographic 
system and the chromatograms were recorded to assess the stability 
of sample (fig. 8 and table 8). 
 
 
Fig. 6: Chromatogram for oxidation degradation study 
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Fig. 7: Chromatogram for alkali degradation study 
 
 
Fig. 8: Chromatogram for dry heat degradation study 
 
Photostability studies 
The photochemical stability of the drug was also studied by exposing 
the (100 µg/ml, 400 µg/ml and 100 µg/ml) solution to UV Light by 
keeping the beaker in UV Chamber for 7days or 200 Watt-hours/m2 
in photostability chamber [21]. For UPLC study, the resultant 
solution was diluted to obtain 100 µg/ml of TZR and 150 µg/ml of 
IVR solution and 1.5 µl solution was injected into the 
chromatographic system and the chromatograms were recorded to 
assess the stability of sample (fig. 9 and table 8). 
  
 
Fig. 9: Chromatogram for photostability study 
Maneka et al. 




Fig. 10: Chromatogram for neutral degradation study 
 
Neutral degradation studies 
Stress testing under neutral conditions was studied by refluxing 
the drug in water for 6 h at a temperature of 60 °C. For UPLC 
study, the resultant solution was diluted to obtain 100 µg/ml of 
TZR and 150 µg/ml of IVR solution and 1.5 µl solution was 
injected into the chromatographic system and the 
chromatograms were recorded to assess the stability of sample 
(fig. 10 and table 8). 
Assay of marketed formulation  
The marketed formulation of Symdeko (tablet) was evaluated by 
infusing 1.5 µl of reference and analyte solutions six times into the 
chromatographic system and the resulting chromatograms of analytes 
were documented [22]. The quantity of anaytes existed in the 
marketed formulation was estimated by equating the peak area of 
reference and analyte. The % assay of TZR and IVR was found to be 
99.0–101.0%.  
CONCLUSION 
A sensitive, rapid and accurate, stability-indicating RP-UPLC method 
for the simultaneous estimation of TZR and IVR in formulations was 
developed and validated as per the ICH guidelines. Retention times 
for TZR and IVR were achieved at 1.071 min and 0.530 min, 
respectively. Mean percentage recovery of TZR and IVR was found to 
be 100.21% and 99.97%, respectively. LOD and LOQ values obtained 
from regression equations of TZR and IVR and were found to be 0.41 
µg/ml/1.23 µg/ml and 0.47 µg/ml/1.44 µg/ml. Regression equation 
of TZR and IVR were: y = 2384.4x+1488, y = 2151x+1552.3 
respectively. Stability studies of these drugs proven that the 
percentage of degradation of analytes were found in between 0.49% 
to 8.41%. Retention time and total run times of analytes were 
decreased. Hence, the developed method was rapid and economical 
that can be applicable in routine analysis of these drugs in quality 
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